Brian L. McClune
( out of 83 reviews )

Brian L. McClune, DO

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City

  • Dr. Brian McClune is an Associate Professor in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah School of Medicine. He was born and raised in Kansas, completing his undergraduate degree in Biochemistry and Medicine there. He completed his Internal Medicine residency at the Johns Hopkins School of Medicine and then went on to a Hematology/Oncology Fellowship at the University of Tennessee where he received specialized training in hematopoietic cell transplantation. Dr. McClune then matriculated to the University of Minnesota where he specialized in stem cell transplantation and treatment of myeloma/plasma cell disorders, was a clinical trialist and director of the Hematology/Oncology Fellowship program over a course of 12 years. He was then promoted to Associate Professor and became a part of the University of Kansas Medical Center before coming to the University of Utah. Dr. McClune is the Associate Chief of Clinical Affairs and the Director of Hematology Clinical Operations. He has over 100 peer-reviewed published articles in various high impact medical journals.

    His research interests are in cellular therapies for hematologic malignancies and abrogating toxicities associated with them He has a special interest in plasma cell disorders treatment including transplantation.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Hematology)

    Patient Rating

    5.0 /5
    ( out of 83 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 24, 2024
    HUNTSMAN CANCER CENTER

    Dr. McClune listened to my concerns and answered my questions. He is thorough with planning.

    July 11, 2024
    HUNTSMAN CANCER CENTER

    He is such a great Doctor! Brilliant in what he does in the Multiple Myeloma Field¿..glad he is in my corner!!!

    July 07, 2024
    HUNTSMAN CANCER CENTER

    He is the of the most caring and wonderful doctors that I have ever met

    June 20, 2024
    HUNTSMAN CANCER CENTER

    Excellent doctor! He was very thorough & caring. I felt that he really knew about multiple myeloma cared about my outcome.

    June 15, 2024
    HUNTSMAN CANCER CENTER

    Dr. McClune provided BMT information in language that I understood while involving me in the conversation and answering my questions. He is good at anticipating questions and was caring. He had his team there for further information and consultation.

    May 25, 2024
    HUNTSMAN CANCER CENTER

    He is a wonderful doc and explains things to you in a way you. Understand

    May 10, 2024
    HUNTSMAN CANCER CENTER

    I would highly recommend Dr McClune!

    May 06, 2024
    HUNTSMAN CANCER CENTER

    Absolutely wonderful physician. And VERY thorough and thoughtful

    May 04, 2024
    HUNTSMAN CANCER CENTER

    Dr. McClune is so kind and gentle. He treats me like I'm his favorite person!

    See More Patient Comments

  • Dr. Brian McClune is an Associate Professor in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah School of Medicine. He was born and raised in Kansas, completing his undergraduate degree in Biochemistry and Medicine there. He completed his Internal Medicine residency at the Johns Hopkins School of Medicine and then went on to a Hematology/Oncology Fellowship at the University of Tennessee where he received specialized training in hematopoietic cell transplantation. Dr. McClune then matriculated to the University of Minnesota where he specialized in stem cell transplantation and treatment of myeloma/plasma cell disorders, was a clinical trialist and director of the Hematology/Oncology Fellowship program over a course of 12 years. He was then promoted to Associate Professor and became a part of the University of Kansas Medical Center before coming to the University of Utah. Dr. McClune is the Associate Chief of Clinical Affairs and the Director of Hematology Clinical Operations. He has over 100 peer-reviewed published articles in various high impact medical journals.

    His research interests are in cellular therapies for hematologic malignancies and abrogating toxicities associated with them He has a special interest in plasma cell disorders treatment including transplantation.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Sub: Hematology)

    Education history

    Fellowship Hematology/Oncology - University of Tennessee Health Science Center Chief Fellow
    Hematology/Oncology - University of Tennessee Health Science Center Fellow
    Residency Internal Medicine - Johns Hopkins University School of Medicine Resident
    Osteopathic Medicine - Kansas City University of Medicine and Biosciences, College of Osteopathic Medicine D.O.
    Undergraduate Biochemistry - Wichita State University B.A.

    Selected Publications

    Journal Article

    1. Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov D (2024). Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. Leuk Lymphoma, 1-4. (Read full article)
    2. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin GR (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leuk Lymphoma, 1-4. (Read full article)
    3. Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR (2022). Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. (Read full article)
    4. McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin GR (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. Eur J Haematol, 109(5), 559-565. (Read full article)
    5. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol, 98(1), 41-48. (Read full article)
    6. Mohyuddin GR, Ahlstrom JM, Chmielewski CA, Sweeney NW, Molina TH, Cheung CS, Ballard EW, Seng FF, Van Oekelen O, Godara A, McClune B, Sborov D (2022). A survey on the patient perspective on cure in multiple myeloma. Lancet Haematol, 9(10), e716-e719. (Read full article)
    7. Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, Abdallah AO, Ganguly S, McGuirk J, Shune L, Mohyuddin GR (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clin Hematol Int, 4(1-2), 56-59. (Read full article)
    8. Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR (2022). Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. Eur J Cancer, 167, 152-160. (Read full article)
    9. Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin GR (2022). Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J, 12(4), 74. (Read full article)
    10. Steinbach M, Julian K, McClune B, Sborov D (2022). Toxicity management Strategies for Next Generation Novel Therapeutics in Multiple Myeloma. Ther Adv Hematol, In Press.
    11. Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin GR (2022). Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J, 2(4): 74.
    12. Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR (2022). Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. Eur J Cancer, 167:152-160.
    13. Barth D, Singleton M, Monohan G, McClune B, Adams V (2022). Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population. Cell Transplant, 31:9636897221080385.
    14. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V (2022). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. . Eur J Cancer (1965), 56:164-174.
    15. Barth D, Singleton M, Monohan G, McClune B, Adams V (2022). Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population. Cell Transplant, 31, 9636897221080385. (Read full article)
    16. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V (2021). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. Eur J Cancer, 156, 164-174. (Read full article)
    17. Mohyuddin GR, Hampton J, Aziz M, Khuder S, Malik S, McClune B, Abdallah AO (2021). A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk, 21(7), 489-496. (Read full article)
    18. Balmaceda N, Aziz M, Chandrasekar VT, McClune B, Kambhampati S, Shune L, Abdallah AO, Anwer F, Majeed A, Qazilbash M, Ganguly S, McGuirk J, Mohyuddin GR (2021). Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer, 21(1), 730. (Read full article)
    19. Bossart A, McClune B, Barrell K, Warner J, Majersik JJ (2021). Pearls & Oy-sters: POEMS Syndrome: An Eloquent Acronym for a Rare Disease You Don't Want to Miss. Neurology, 97(17), 835-838. (Read full article)
    20. Mohyuddin GR, Koehn K, Shune L, Aziz M, Abdallah AO, McClune B, Ganguly S, McGuirk J, Kambhampati S (2021). Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019. Leuk Lymphoma, 62(6), 1386-1395. (Read full article)
    21. Mohyuddin GR, Koehn K, Abdallah AO, W Sborov D, Rajkumar SV, Kumar S, McClune B (2021). Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. Am J Hematol, 96(6), 690-697. (Read full article)
    22. Mohyuddin GR, Abdallah AO, McClune B (2021). Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma. JAMA Oncol, 7(4), 635. (Read full article)
    23. Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad V (2020). Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematol, 8(4), e299-e304. (Read full article)
    24. Abbasi S, Roller J, Abdallah AO, Shune L, McClune B, Sborov D, Mohyuddin GR (2021). Hospitalization at the end of life in patients with multiple myeloma. BMC Cancer, 21(1), 339. (Read full article)
    25. Mohyuddin GR, Rooney A, Balmaceda N, Aziz M, Sborov DW, McClune B, Kumar SK (2020). Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood Adv, 5(4), 1097-1101. (Read full article)
    26. Mohyuddin GR, Abbasi S, Okoniewski M, McClune B, Abdallah AO, Ganguly S, McGuirk J, Shune L (2020). Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation. Eur J Haematol, 105(5), 571-577. (Read full article)
    27. Mohyuddin GR, Koehn K, Costa L, Kumar SK, McClune B (2020). Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change. Lancet Haematol, 7(10), e704-e706. (Read full article)
    28. Britt A, Mohyuddin GR, McClune B, Singh A, Lin T, Ganguly S, Abhyankar S, Shune L, McGuirk J, Skikne B, Godwin A, Pessetto Z, Golem S, Divine C, Dias A (2020). Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Leuk Res, 95, 106402. (Read full article)
    29. Mohyuddin GR, Dominick A, Black T, Hoffman M, Male H, Byrd K, McClune B, Eck L, Neupane P (2020). A Critical Appraisal and Targeted Intervention of the Oncology Experience in an Internal Medicine Residency. J Cancer Educ. (Read full article)
    30. Mohyuddin GR, Aziz M, McClune B, Abdallah AO, Qazilbash M (2020). Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta-analysis. Eur J Haematol, 104(5), 420-426. (Read full article)
    31. Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM (2018). Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Adv, 3(6), 875-883. (Read full article)
    32. Santiago V, Lazaryan A, McClune B, McKenna RW, Courville EL (2017). Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome. Leuk Lymphoma, 59(4), 958-966. (Read full article)
    33. He F, Cao Q, Lazaryan A, Brunstein C, Holtan S, Warlick E, Ustun C, McClune B, Arora M, Rashidi A, Eckfeldt C, Weisdorf DJ, Bejanyan N (2017). Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index. Biol Blood Marrow Transplant, 23(9), 1485-1490. (Read full article)
    34. Belete H, Burns LJ, Shanley R, Nayar M, McClune B, Lazaryan A, Bachanova V, Bejanyan N, Ustun C, Brunstein C, Weisdorf DJ, Arora M (2017). Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients. Am J Hematol, 92(9), E529-E533. (Read full article)
    35. Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL (2017). Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol, 4(9), e431-e442. (Read full article)
    36. Hegerova L, Cao Q, Lazaryan A, McClune BL, Weisdorf DJ, Brunstein CG, Bachanova V (2017). Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. Bone Marrow Transplant, 52(5), 697-703. (Read full article)
    37. Fair C, Shanley R, Rogosheske J, Lazaryan A, McClune B, Brunstein CG, Bachanova V (2017). BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications. Bone Marrow Transplant, 52(3), 491-493. (Read full article)
    38. Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA (2015). Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res, 21(6), 1267-72. (Read full article)
    39. Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, Stadtmauer EA, Vesole DH, Logan B, Weisdorf D, Qazilbash M, Popplewell LL, McClune B, Bensinger W, Riches M, Giralt SA, Pasquini MC, Resource for Clinical Investigation in Blood and Marrow Transplantation (2014). Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, 20(8), 1183-9. (Read full article)
    40. McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ (2014). Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant, 20(7), 960-8. (Read full article)
    41. McClune BL, Majhail NS (2013). Osteoporosis after stem cell transplantation. Curr Osteoporos Rep, 11(4), 305-10. (Read full article)
    42. Sung AD, Grima DT, Bernard LM, Brown S, Carrum G, Holmberg L, Horwitz ME, Liesveld JL, Kanda J, McClune B, Shaughnessy P, Tricot GJ, Chao NJ (2013). Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. Bone Marrow Transplant, 48(11), 1444-9. (Read full article)
    43. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C (2012). Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med, 366(19), 1770-1781. (Read full article)
    44. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C (2012). Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med, 366(19), 1770-81. (Read full article)
    45. Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, Warlick ED, Wagner JE, Weisdorf DJ (2011). Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant, 47(4), 494-8. (Read full article)
    46. McClune B, Majhail NS, Flowers ME (2012). Bone loss and avascular necrosis of bone after hematopoietic cell transplantation. Semin Hematol, 49(1), 59-65. (Read full article)
    47. Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M, Bachanova V, Brunstein C, Burns L, Cooley S, Kaufman D, Majhail NS, McClune B, McGlave P, Miller J, Oran B, Slungaard A, Vercellotti G, Weisdorf DJ (2010). Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant, 17(7), 1025-32. (Read full article)
    48. McClune BL, Polgreen LE, Burmeister LA, Blaes AH, Mulrooney DA, Burns LJ, Majhail NS (2010). Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant, 46(1), 1-9. (Read full article)
    49. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, Dipersio J, Keating A, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Waller EK, Bredeson C, Giralt S (2010). Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol, 28(11), 1878-87. (Read full article)
    50. McClune BL, Weisdorf DJ (2010). Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care? Curr Opin Hematol, 17(2), 133-8. (Read full article)
    51. Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B, Burns LJ, Tomblyn M, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE (2008). Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant, 15(2), 214-22. (Read full article)
    52. Przepiorka D, Buadi FK, McClune B (2007). Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia. Pharmacotherapy, 28(1), 58-63. (Read full article)
    53. Przepiorka D, Buadi F, McClune B, Franz G, Walsh W, White F (2007). Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Bone Marrow Transplant, 40(8), 759-64. (Read full article)

    Review

    1. Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, McClune B, Kelkar AH, Sborov D, Mohyuddin GR (2023). Multiple Myeloma in Young Patients: A Scoping Review. [Review]. Clin Lymphoma Myeloma Leuk, 24(1), 15-22. (Read full article)
    2. Steinbach M, Julian K, McClune B, Sborov DW (2022). Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. [Review]. Ther Adv Hematol, 13, 20406207221100659. (Read full article)
    3. Steinbach M, Julian K, McClune B, Sborov DW (2022). Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. [Review]. Ther Adv Hematol, 13. (Read full article)

    Book Chapter

    1. McClune BL (2015). Plasma cell neoplasms, a therapeutic approach. In McClune BL (Ed.), Plasma Cell Neoplasms: A Morphologic, Cytogenetic and Immunophenotypic Approach (pp. 123-141). (Read full article)
    2. McClune BL (2014). Clinical Considerations in Myeloma Care. In Plasma Cell Neoplasms. Springer.
    3. McClune BL (2014). Blood versus Marrow Allogeneic Stem Cell Transplantation. In Lazarus HM, Laughlin, MJ (Eds.), Allogeneic Stem Cell Transplantation: Clinical Research Practice (2nd Edition, pp. 281-97). Humana Press.

    Letter

    1. Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, Abdallah AO, Ganguly S, McGuirk J, Shune L, Mohyuddin GR (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma [Letter to the editor]. Clin Hematol Int, 4(1-2), 56-59. (Read full article)
    2. Mohyuddin GR, Abdallah AO, McClune B, Goodman A, Prasad V (2020). Multiple myeloma triplet therapies: baseline characteristics and control groups. [Letter to the editor]. Lancet, 397(10285), 1620-1621. (Read full article)
    3. Mohyuddin GR, Okoniewski M, Diab O, Ganguly S, Shune L, Abdallah AO, McGuirk J, McClune B (2020). Maintenance regimens after a second autologous transplant for multiple myeloma. [Letter to the editor]. Leuk Lymphoma, 62(3), 758-760. (Read full article)
    4. Mohyuddin GR, Abbasi S, Ripp J, Singh A, Kambhampati S, McClune B (2020). Patients with leukemia dying in the hospital: results of the national inpatient sample and a call to do better. [Letter to the editor]. Leuk Lymphoma, 61(11), 2760-2762. (Read full article)
    5. Mohyuddin GR, Sigle M, Chandrasekar VT, Aziz M, Abdallah AO, Shune L, McClune B (2020). Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis. [Letter to the editor]. Leuk Lymphoma, 61(10), 2519-2522. (Read full article)
    6. Abbasi S, Britt A, McClune B, Shune L, Kambhampati S, Mohyuddin GR (2020). Inpatient hospitalization's associated cost and mortality in myeloma patients undergoing autologous stem cell transplant: a 13-year analysis of the National Inpatient Sample. [Letter to the editor]. Leuk Lymphoma, 61(5), 1254-1256. (Read full article)
    7. McClune BL, Defor T, Brunstein C, Vogel RI, Majhail NS, Bachanova V, Burns LJ, Slungaard A, Weisdorf DJ (2011). Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting. [Letter to the editor]. Br J Haematol, 156(2), 273-5. (Read full article)
    8. McClune B, Buadi FK, Aslam N, Przepiorka D (2007). Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. [Letter to the editor]. Leuk Lymphoma, 48(9), 1849-51. (Read full article)

    Abstract

    1. Stadtmauer EA, Pasquini MC, Blackwell B, Knust K, Bashey A, Devine SM, Efebera YA, Ganguly SGasparetto C, Geller N, Giralt SAHari PH, Horowitz MH, Koreth JLandau H, McCarthy P, McClune B, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Somlo G, Krishnan A (2016). Comparison of Autologous Hematopoietic Cell Transplant (auto HCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Auto Hct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial) [Abstract]. 128, LBA1.
    2. Shune L, Weisdorf DJ, McClune B, et al (2009). Allogeneic hematopoietic cell transplant for multiple myeloma: Comparative results of planned therapy versus salvage therapy [Abstract]. 27(15s), suppl; abstract 7035.
    3. McClune B, Burns L, Defor T, Slungaard A, Bachanova V, Brunstein B, Weisdorf D (2009). Hematopoietic cell transplantation for chronic lymphocytic leukemia: similar efficacy of non- myeloablative and myeloablative conditioning; long-term evaluation from the University of Minnesota [Abstract]. 114, abstract 3385.
    4. Waheed S, McClune B, Buadi F, Wright K, Przepiorka D (2006 (June 20 Supplement)). The effect of changes in the treatment paradigm for chronic lymphocytic leukemia: A tumor registry study [Abstract]. 24(18S), 16000.
    5. Crenshaw C, Brenner S, McClune B, Bradley R, Przepiorka D (2006). In vivo validation of single platform measurement of CD34 in peripheral blood stem cells [Abstract]. 8, 54.
    6. Buadi F, McClune B, Hull Y, Yunus F, Minhas S, Przepiorka D (2005). The addition of rituximab to standard high dose BEAM chemotherapy for autologous stem cell transplant in patients with lymphoma does have a significant effect on engraftment [Abstract]. 106, 5325.
    7. McClune B, Buadi F, Hull Y, Yunus F, Minhas S, Walsh W, Przepiorka D (2005). The natural history of relapse after transplantation for myeloma [Abstract]. 106, 5511.
    8. McClune B, Kumar B, Buadi F, Womeodu R, Wright K, Baskin R, Minhas S, Ratliff TW, Spiers K, Yunus F, Przepiorka D (2004). African Americans and Caucasians with myeloma have similar outcomes in the current era: A tumor registry study [Abstract]. 104, abstract 857.
    9. Buadi F, McClune B, Moore Y, Womeodu R, Yunus F, Walsh W, Minhas S, Przepiorka D (2004). Race has no effect on survival in multiple myeloma patients undergoing autologous stem cell transplantation [poster presentation also given at American Society of Hematology Annual Meeting, San Diego CA] [Abstract]. 104, abstract 357.